The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: A retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen

Bruno Vincenzi, Santini Daniele, Anna Maria Frezza, Pierpaolo Berti, Umberto Vespasiani, Antonio Picardi, Giuseppe Tonini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Hepatotoxicity represents a frequent chemotherapy-related side effect, often associated with course delays, discontinuations, and dose reductions. S-adenosylmethionine (AdoMet) administration is effective in the treatment of a variety of liver injuries, but it has never been evaluated in the prevention of chemotherapy-induced damage. Patients and methods: Seventy-eight patients affected by metastatic colorectal cancer were enrolled. Forty-two patients were treated with bevacizumab and XELOX without administering AdoMet, 32 were treated with the same regimen plus supplementation with AdoMet. Liver enzymes levels were assessed before starting the treatment, and then every therapy cycle, liver toxicity, chemotherapy course delays, discontinuations, and dose reductions due to liver toxicity were recorded. Results: Aspartate aminotransferase (P=0.02), alanine trans-aminase (P

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalSupportive Care in Cancer
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2012

Keywords

  • Hepatotoxicity
  • Oxaliplatin
  • S-adenosylmethionine

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: A retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen'. Together they form a unique fingerprint.

Cite this